drugset / Trial / NCT03651882

Oxytocin i.m./i.v. Versus Carbetocin i.v. in Elective Cesarean Sections

NCT03651882

Phase 4 Completed 550 enrolled University of Zurich
RandomizedParallel-groupOpen-labelPrevention

Summary

Objective is to proof non-inferiority of intramyometrial and intravenous oxytocin application compared to intravenous carbetocin for prevention of postpartum hemorrhage in planned, uncomplicated cesarean deliveries.

Timeline

Start
2018-08-07
Primary completion
2022-01-10
Completion
2022-01-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Carbetocin Peptide 0.1 mg Intravenous
Comparator Oxytocin Peptide 10 iu Other

Indications

No indication recorded.